ContraFect Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
559.20
551.30
537.30
451.00
187.20
151.30
Gross Income
559.20
551.30
537.30
451.00
187.20
151.30
SG&A Expense
18,737.20
16,384.60
23,928.00
33,081.20
26,376.50
32,195.10
EBIT
19,296.40
16,935.90
24,465.30
33,532.30
26,563.80
32,346.40
Unusual Expense
2,612.10
1,225.20
731.30
6,346.60
11,533.00
7,232.20
Non Operating Income/Expense
-
424.70
-
1,569.30
905.00
1,222
Interest Expense
1,712.20
12,412.60
-
-
-
-
Pretax Income
23,620.70
30,149.10
25,121.00
28,538.40
15,517.70
37,684.40
Consolidated Net Income
23,620.70
30,149.10
25,121.00
28,538.40
15,517.70
37,684.40
Net Income
23,620.70
30,149.10
25,121.00
28,538.40
15,517.70
37,684.40
Net Income After Extraordinaries
23,620.70
30,149.10
25,121.00
28,538.40
15,517.70
37,684.40
Net Income Available to Common
23,620.70
34,617.50
25,121.00
28,538.40
15,517.70
37,684.40
EPS (Basic)
3.34
3.86
1.08
0.85
0.28
0.50
Basic Shares Outstanding
38,966.70
8,973.60
23,328.90
33,539.50
55,595.70
76,062.70
EPS (Diluted)
0.61
3.86
1.08
0.85
0.28
0.50
Diluted Shares Outstanding
38,966.70
8,973.60
23,328.90
33,539.50
55,595.70
76,062.70
EBITDA
18,737.20
16,384.60
23,928.00
33,081.20
26,376.50
32,195.10
Non-Operating Interest Income
-
-
75.70
216.60
418.10
672.20
Preferred Dividends
-
4,468.50
-
-
-
-

About ContraFect

View Profile
Address
28 Wells Avenue
Yonkers New York 10701
United States
Employees -
Website http://www.contrafect.com
Updated 07/08/2019
ContraFect Corp. engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.